Oxis Turbohaler (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate, the active ingredient in Oxis Turbohaler, is a long‑acting β2‑adrenergic agonist presented as a dry‑powder inhaler for inhalation use. It provides bronchodilation for patients with asthma and chronic obstructive pulmonary disease. GNH USA supplies Oxis Turbohaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Oxis Turbohaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Formoterol fumarate dihydrate is a bronchodilator that acts on the airway smooth‑muscle pathway to improve airflow in obstructive lung disease.

- Asthma: improves symptom control and reduces the need for rescue inhaler use. - Chronic obstructive pulmonary disease (COPD): provides sustained bronchodilation and helps decrease exacerbation frequency. - Exercise‑induced bronchoconstriction: maintains airway patency during physical activity.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Tremor: mild, transient shaking of the hands. - Headache: dull or pressure‑type headache. - Throat irritation: mild discomfort or dryness in the throat. - Cough: occasional dry cough after inhalation. - Palpitations: sensation of rapid or irregular heartbeat. - Nasal congestion: mild blockage of the nasal passages.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing difficulty. - Cardiovascular events: arrhythmia, angina, or hypertension. - Hypokalemia: low blood potassium levels. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Hyperglycaemia: elevated blood glucose in susceptible individuals. - Pulmonary oedema: fluid accumulation in the lungs.

When using Oxis Turbohaler, consider the following safety measures:

- Assess respiratory status: confirm diagnosis and severity before initiating therapy. - Review cardiac history: patients with arrhythmias or coronary disease need careful monitoring. - Monitor potassium levels: especially in patients on diuretics or with renal impairment. - Avoid abrupt discontinuation: sudden cessation may worsen bronchospasm. - Educate on inhaler technique: ensure correct use to maximise drug delivery. - Store at ambient temperature: keep below 25°C, protect from moisture and direct sunlight.

Formoterol may interact with several drug classes; clinicians should evaluate potential risks.

Major Interactions (Avoid): - Non‑selective β‑blockers: may diminish bronchodilator effect and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs): can increase risk of cardiovascular side effects.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate hypokalemia. - Theophylline: additive stimulant effect on the heart. - Anticholinergic bronchodilators: may increase risk of tachycardia. - Corticosteroids: combined use may enhance systemic exposure. - Antidepressants (SSRIs): potential for mild QT‑interval changes.